Casein kinase Iα inhibitors belong to a significant chemical class characterized by their capacity to selectively target and modulate the activity of the enzyme casein kinase Iα (CKIα). This enzyme is a serine/threonine protein kinase that plays a crucial role in regulating various cellular processes, including signal transduction, cell division, circadian rhythms, and gene expression. The inhibitors within this chemical class are designed to interact with the active site of CKIα, thereby obstructing its enzymatic function and interrupting downstream signaling cascades. Structurally, casein kinase Iα inhibitors often possess a heterocyclic core scaffold, which is meticulously optimized to complement the binding site of the enzyme. This allows for favorable interactions such as hydrogen bonding, van der Waals forces, and hydrophobic interactions with key residues within the active site. The inhibitors' chemical diversity arises from modifications made to this core scaffold, enabling researchers to fine-tune the compound's potency, selectivity, and pharmacokinetic properties. These inhibitors are often synthesized using organic chemistry techniques, and their three-dimensional structures are determined through X-ray crystallography or other spectroscopic methods. Additionally, computational modeling plays a pivotal role in predicting the interactions between the inhibitors and CKIα, facilitating the rational design of new compounds with enhanced affinity and specificity.
The significance of casein kinase Iα inhibitors lies in their ability to dissect and elucidate complex cellular pathways that CKIα regulates. By perturbing CKIα activity, researchers can gain insights into the specific roles of this kinase in various physiological and pathological processes. Furthermore, these inhibitors serve as valuable tools in understanding the intricacies of CKIα's substrate specificity and its interactions with other cellular components.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide | 120615-25-0 | sc-207901 | 10 mg | $380.00 | ||
A commonly used CKIα inhibitor, CKI-7 competes with ATP to inhibit CKIα activity, helping researchers study its roles in cellular processes. | ||||||
Cdc2-Like Kinase Inhibitor, TG003 | 300801-52-9 | sc-202528 sc-202528A | 5 mg 25 mg | $139.00 $548.00 | 6 | |
This inhibitor targets CKIα and CKIε isoforms, blocking CKIα's kinase activity by binding to its ATP-binding site. | ||||||
PF 4800567 | 1188296-52-7 | sc-362782 sc-362782A | 5 mg 25 mg | $172.00 $492.00 | ||
A potent selective CKIα inhibitor, PF-4800567 competes with ATP, showing anticancer potential by disrupting signaling pathways. | ||||||
Casein Kinase I Inhibitor, D4476 | 301836-43-1 | sc-202522 | 1 mg | $99.00 | 6 | |
A selective CKIα inhibitor, D4476 competes with ATP, aiding the study of CKIα's involvement in cellular processes. | ||||||
PF 670462 | 950912-80-8 | sc-204180 sc-204180A | 10 mg 50 mg | $198.00 $808.00 | 9 | |
This compound selectively inhibits CKIα by binding to its kinase domain, blocking its enzymatic activity. | ||||||
IC261 | 186611-52-9 | sc-3561 | 5 mg | $140.00 | 11 | |
IC261 prevents CKIα-mediated substrate phosphorylation, showing promise in cancer therapy. | ||||||
PHA-793887 | 718630-59-2 | sc-364580 sc-364580A | 5 mg 10 mg | $189.00 $432.00 | ||
With anticancer properties, PHA-793887 induces cell cycle arrest and apoptosis by inhibiting CKIα. | ||||||
CKI-7 dihydrochloride | 1177141-67-1 | sc-252621 sc-252621A | 5 mg 10 mg | $280.00 $320.00 | 5 | |
Similar to CKI-7, this form suppresses CKIα activity by targeting its ATP-binding site. | ||||||
PF-4800567 Hydrochloride | 1391052-28-0 | sc-477581 | 10 mg | $320.00 | ||
A salt form of PF-4800567, it retains inhibitory activity against CKIα and downstream pathways. | ||||||